Jessica K. Altman, MD

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, highlight other key AML data from the 2025 ASH Annual Meeting.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential dose modification approaches for the use of triplet therapy in AML.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential treatment strategies in AML following triplet therapy and transplant.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential triplet strategies with menin inhibitors for KMT2A-rearranged AML.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss data for venetoclax plus azacitidine vs induction chemotherapy in newly diagnosed, fit AML.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, detail populations in AML that could derive benefit from triplet therapies.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss data from MD Anderson Cancer Center on triplet therapies in AML with IDH mutations.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss the rationale for investigating triplet therapies in acute myeloid leukemia.

Jessica K. Altman, MD, associate professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern Medicine, discusses an early-phase study of gilteritinib in FLT3-mutation–positive patients with acute myeloid leukemia (AML).